Type 2 & other diabetes

Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes

J Clin Endocrinol MetabPublished Randomised controlled trial

Primary result · Insulin secretion (incremental AUC for insulin) during hyperglycemic clamp, with trainingResult — go to the resultMedian increase in total insulin secretion, difference 134 nM × 2 hours 95% CI 108–232

Authors' conclusion

The combination of aerobic training and semaglutide treatment synergistically improved β-cell secretory function.

Study context

Population
Patients with T2D
Participants
31 patients
Comparison
Aerobic training alone vs semaglutide treatment (20 weeks) followed by concurrent semaglutide and aerobic training
Primary endpoint
Change in insulin secretory capacity with training, by 2-stepped hyperglycemic (20 and 30 mM) clamp
Follow-up
12 weeks of training

Primary result

As reported in the abstract

Insulin secretion (incremental AUC for insulin) during hyperglycemic clamp, with training · before vs after training

Median increase in total insulin secretion, difference

134 nM × 2 hours

95% CI 108–232

Semaglutide and trainingvs Training
median increase in total insulin secretion, difference 134 nM × 2 hours (95% CI 108–232)
Training: insulin AUC, clamp step 1, 21 to 27 nM × 2 hours
ratio 1.28, 95% CI 1.02-1.60
Training: insulin AUC, clamp step 2, 40 to 64 nM × 2 hours
ratio 1.61, 95% CI 1.25-2.07
Semaglutide and training: insulin secretion, step 1, 130 to 171 nM × 2 hours
ratio 1.31, 95% CI 1.06-1.63
Semaglutide and training: insulin secretion, step 2, 525 to 697 nM × 2 hours
ratio 1.33, 95% CI 1.02-1.72

Further findings

Insulin secretion with semaglutide treatment (before training) · 20 weeks of semaglutide

Clamp step 1, 16 to 111 nM × 2 hours
ratio 7.10, 95% CI 3.68-13.71
Clamp step 2, 35 to 447 nM × 2 hours
ratio 12.74, 95% CI 5.65-28.71

Original publication

Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. Published 2 June 2023. doi:10.1210/clinem/dgad326

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.